Immediate Impact
11 from Science/Nature 66 standout
Citing Papers
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
2023 Standout
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
2022 Standout
Works of T. Hirashima being referenced
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
2019
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| T. Hirashima | 890 | 651 | 558 | 54 | 1.2k | |
| Philip Bonomi | 584 | 399 | 585 | 36 | 1.2k | |
| Kuan‐Yu Chen | 499 | 562 | 307 | 38 | 1.0k | |
| V. Damiano | 791 | 561 | 497 | 31 | 1.3k | |
| Adrian Langleben | 703 | 402 | 309 | 54 | 1.1k | |
| Paul Conkling | 1136 | 638 | 509 | 93 | 1.7k | |
| Pallavi S. Mishra‐Kalyani | 844 | 537 | 312 | 49 | 1.4k | |
| E Kr̆epela | 695 | 415 | 495 | 46 | 1.5k | |
| Jan Cosaert | 1029 | 630 | 433 | 43 | 1.5k | |
| Sachdev Thomas | 860 | 502 | 476 | 58 | 1.3k | |
| Takuro Kometani | 616 | 589 | 551 | 43 | 1.2k |
All Works
Loading papers...